NCT04871113 - A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

October 27, 2022

Study Completion Date

September 21, 2023

Conditions

HIV Infections

Interventions

BIOLOGICAL

GSK3810109A

GSK3810109A available as sterile aqueous solution.

BIOLOGICAL

Dolutegravir+lamivudine SOC regimen

Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines

Trial Locations (24)

1023

GSK Investigational Site, Buenos Aires

5400

GSK Investigational Site, San Juan

7600

GSK Investigational Site, Mar del Plata

11030

GSK Investigational Site, Manhasset

32803

GSK Investigational Site, Orlando

48072

GSK Investigational Site, Berkley

66278

GSK Investigational Site, Monterrey

75246

GSK Investigational Site, Dallas

90027

GSK Investigational Site, Los Angeles

90036

GSK Investigational Site, Los Angeles

90813

GSK Investigational Site, Long Beach

97000

GSK Investigational Site, Mérida

C1181ACH

GSK Investigational Site, Buenos Aires

C1202ABB

GSK Investigational Site, Buenos Aires

C1425AGC

GSK Investigational Site, Buenos Aires

C1405CKC

GSK Investigational Site, Ciudad Autonoma de Bueno

S2000PBJ

GSK Investigational Site, Rosario

21045-900

GSK Investigational Site, Rio de Janeiro

05403-010

GSK Investigational Site, São Paulo

K1H 8L6

GSK Investigational Site, Ottawa

M5G 2N2

GSK Investigational Site, Toronto

H4A 3J1

GSK Investigational Site, Montreal

S4P 0W5

GSK Investigational Site, Regina

Lima 4

GSK Investigational Site, Lima